Team McCallum

R&D for Lifetime of Life

The next diet drugs?

Qnexa is under review by the FDA at this very moment. Lorcaserin is scheduled for FDA review in mid-September. Contrave should be reviewed sometime between mid-September and early 2011.

The study results for lorcaserin were published in the New England Journal of Medicine today.

To gain approval, the drugs must pass safety checks and pass at least one of two tests
– patients should lose at least 5% more of their bodyweight compared to a placebo
– at least 35% of patients taking the drug should lose at least 5% of their bodyweight and the number doing so must at least double the number achieving this on a placebo.

Due to different study designs (e.g. different meanings of ‘placebo’), drug trials are not directly comparable.

However, Qnexa and Contrave passed both tests, whereas lorcaserin passed only the second.

In effectiveness terms, lorcaserin averaged a 12.8lb loss over one year, compared to 4.8lbs in the placebo group. While this appears low, lorcaserin had a good safety profile (something of a problem area for previous diet drugs) and improved a number of cardiovascular disease markers.


July 15, 2010 - Posted by | Contrave, CVD - cardiovascular disease, Lorcaserin, News, Obesity, Qnexa, Weight management


  1. The next diet drugs? « Team McCallum…

    I found your entry interesting do I’ve added a Trackback to it on my weblog :)…

    Trackback by All Around the World News | July 15, 2010 | Reply

  2. i like your blog 🙂 keep it up. i have a blog on diet visit mine sometime

    Comment by Nicole | July 17, 2010 | Reply

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: